Drug-eluting stents appear superior to bare metal stents for vein-graft PCI in vessels up to a stent diameter of 4 mm
Abstract
Overview
Background. Research trials have shown improved short-term outcome with drug-eluting stents (DES) over bare
metal stents (BMS) in saphenous vein graft (SVG) percutaneous coronary intervention (PCI), primarily by reducing
target vessel revascularization (TVR) for in-stent restenosis. We compared the outcomes in patients undergoing
SVG stent implantation treated with DES or BMS. In exploratory analyses we investigated the influence of stent
generation and diameter.
Methods. Data were obtained from a prospective database of 657 patients who underwent PCI for SVG lesions
between 2003 and 2011. A total of 344 patients had PCI with BMS and 313 with DES. Propensity scores were developed
based on 15 observed baseline covariates in a logistic regression model with stent type as the dependent
variable. The nearest-neighbour-matching algorithm with Greedy 5-1 Digit Matching was used to produce two patient
cohorts of 313 patients each. We assessed major adverse cardiac events (MACE) out to a median of 3.3 years
(interquartile range: 2.1-4.1). MACE was defined as all-cause mortality, myocardial infarction (MI), TVR and stroke.
Results. There was a significant difference in MACE between the two groups in favour of DES (17.9% DES vs.
31.2% BMS group; p = 0.0017) over the 5-year follow-up period. MACE was driven by increased TVR in the BMS
group. There was no difference in death, MI or stroke. Adjusted Cox analysis confirmed a decreased risk of MACE
for DES compared with BMS 0.75 (95% confidence interval (CI) 0.52-0.94), with no difference in the hazard of allcause
mortality (hazard ratio: 1.08; 95% CI: 0.77-1.68). However, when looking at stent diameters greater than
4 mm, no difference was seen in MACE rates between BMS and DES.
Conclusions. Overall in our cohort of patients who had PCI for SVG disease, DES use resulted in lower MACE rates
compared with BMS over a 5-year follow-up period; however, for stent diameters over 4 mm no difference in
MACE rates was seen.
Keywords
Bare metal stent, Drug-eluting stent, Percutaneous intervention, Stroke, Target vessel revascularisation, Venous graft
Article Information
Disclosure
Financial support: No grants or funding have been received for this
study.
Correspondence
Dr. Roshan Weerackody Barts Heart Centre Barts Health NHS Trust West Smithfield EC1A 7BE, London, UK Roshan.weerackody@bartshealth.nhs.uk
Further Resources
Trending Topic
After decades of debate, patent foramen ovale (PFO) closure is now a well-established strategy to reduce recurrent stroke in patients aged 18–60 years who have had a PFO-associated stroke.1 Patients who underwent PFO closure continue to have a higher stroke risk than the general population. A recent study demonstrated a 2.1% higher stroke rate in the […]
After decades of debate, patent foramen ovale (PFO) closure is now a well-established strategy to reduce recurrent stroke in patients aged 18–60 years who have had a PFO-associated stroke.1 Patients who underwent PFO closure continue to have a higher stroke risk ...
Cardiovascular medicine continues to advance at a remarkable pace, driven by innovation, interdisciplinary collaboration and an ever-deepening understanding of disease mechanisms. As patient populations age and chronic conditions become increasingly complex, the field stands at the intersection of precision therapy, ...
Cardiovascular medicine stands at a pivotal crossroads—shaped by rapid advances in precision therapies, a deepening understanding of disease mechanisms, and an urgent imperative to address global health disparities. As the burden of cardiovascular disease continues to evolve, so too ...
Conduction system pacing (CSP) is being increasingly adopted as a more physiological alternative to right ventricular and biventricular pacing and is an integral part of the European Heart Rhythm Association (EHRA) core curriculum for the device specialist.1–6 Left bundle branch ...
Welcome to this issue of Heart International. As ever, we aim to provide our readers with the latest developments, insights, and evidence-based discussions in cardiovascular care. This edition is particularly poignant, as we begin with a heartfelt tribute to an ...
Forty-seven years ago, Andreas Gruentzig introduced ‘percutaneous transluminal coronary angioplasty’ (PTCA) as a new approach to treating symptomatic occlusive coronary artery disease.1 The mechanism of balloon angioplasty (BA) formed the foundation around which newer equipment and technologies were developed, including ...
Tricuspid regurgitation (TR) is a frequent finding on echocardiography, with detection rates reaching up to 86% across the different ranges of severity, with moderate or greater TR being reported in at least 6–8% of patients.1–3 The prevalence of TR increases with age, ...
Cardiovascular diseases are the most common cause of mortality and morbidity in adults worldwide.1Â Coronary angiography (CAG) is the gold standard method for evaluating atherosclerotic coronary artery disease (CAD).2Â It is conventionally performed via the trans-femoral (TF) route. Recently, however, ...
We are sorry to announce the death of one of our valued editorial board members, Dr Richard Heuser (November 17, 1950–May 23, 2024). Richard R Heuser, MD, FACC, FACP, FESC, MSCAI, was an internationally recognized cardiologist, inventor, educator and author, and was a ...
Welcome to the summer issue of Heart International. We are excited to present a collection of insightful articles that delve into various aspects of cardiovascular health and related interventions. This issue encompasses a wide array of topics, from novel treatment ...
Clinically relevant tricuspid regurgitation (TR) is a common disorder, affecting approximately 4% of people 75 years of age or older.1Â If left untreated, severe TR results in volume overload and right ventricular remodelling. This eventually leads to symptomatic right-sided heart failure, along ...
In this issue of Heart International, we are delighted to present a collection of insightful articles that encompass a wide spectrum of topics within the field of cardiovascular medicine. As we navigate the landscape of cardiovascular disease, heart failure, preventative ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
